ClinicalTrials.gg
CompletedNCT06526260Updated Oct 28, 2026

Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth

An interventional study of Very Brief Exposure to Facial Expressions in Social Anxiety Disorder, sponsored by Children's Hospital Los Angeles. Completed at 1 site in United States. Open to participants aged 16 Years to 22 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Children's Hospital Los Angeles · Not applicable, Interventional, and Basic science

How we know

Updated Oct 28, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
16 Years to 22 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 187 studies in Phobia, Social with a site in United States — 23 open to participants now, 29 under way, 1 of them phase 3. Phobia, Social · United States.

Enrollment
57th of 178
120 · median 64
Started
2024
with 14 others
No phase
100 of 187
17 open now
Registered
165th of 187
by date

Among the 187 studies in Phobia, Social with a site in United States, this one is the 57th largest by enrollment of the 178 interventional ones that give a count, is one of 15 that started in 2024, is one of 100 with no phase, and was the 165th registered.

Phobia, Social

368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.

Browse Phobia, Social studies →

Open to participants now

23 of the 187 studies in Phobia, Social with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.

This study: 16 Years to 22 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Phobia, Social with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to identify the circuit activations by very brief exposure (VBE) among youth with social anxiety disorder (SAD) in order to develop a novel intervention for those with SAD. The secondary objectives of this study are to measure the effect of VBE on subjective fear ratings, and participants' awareness and tolerance of the exposure stimuli.

  • The primary outcome of this study is the mean activation of frontostriatal and prefrontal brain regions to facial stimuli, as measured by Blood Oxygen Level Dependent (BOLD) response, in 4 regions of interest during the magnetic resonance imaging (MRI).
  • Another primary outcome of the study is to identify networks of regions subserving emotion regulation and attention, as measured by BOLD response of corresponding brain regions.

Secondary Outcomes

-The secondary outcome of this study is the fear induced by exposure to facial expression stimuli as measured by a 4-point fear scale during the functional magnetic resonance imaging (fMRI) after each block of 10 facial expression stimuli trials.

Participants will participate in an interview where they will answer questions both inside and outside of the MRI scan. Participants will be asked to rate on a scale the imagines they see while undergoing MRI scan.

03

Conditions studied

  • Social Anxiety Disorder

Browse trials for

Keywords

  • Youth
  • Very Brief Exposure
04

Who can participate

Ages eligible
16 Years to 22 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient Population

    • Males and females aged 16-22. This age range corresponds with our prior studies of very brief exposure (VBE) in Specific Phobia and will include older adolescents while minimizing potential developmental effects on circuit activation.
    • Youth with a (DSM-5) diagnosis of Social Anxiety Disorder (SAD) on Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children, Computerized version (K-SADS-COMP) for youth ages 16-17, or the computerized version of Structured Clinical Interview for the DSM-5 (NetSCID) for youth ages 18+.
  • Healthy Population

    • Male and female youth aged 16-22.
  • Parents • Parent/caregiver of all ages, no restrictions who are fluent in either English or Spanish.

Exclusion criteria

Exclusion Criteria:

  • Patient Population

    • Primary language other than English or Spanish.
    • Active suicidality on the Colombia-Suicide Severity Scale (plan, intent, or behavior)
    • Ferromagnetic implants (e.g., pacemaker), metal braces, retainers, tattoos or permanent make-up with metallic content, transdermal medicinal patches that cannot be removed.
    • Current psychoactive medication.
    • Lifetime diagnosis of: obsessive-compulsive disorder (OCD), psychotic, bipolar, autism spectrum disorder, intellectual disability on the KSADS-COMP or NetSCID.
    • Any serious neurological or medical conditions (e.g., Lupus, cancer, positive (HIV+)) as reported by potential participants.
    • Current Post-Traumatic Stress Disorder (PTSD) diagnosis.
    • Current severe substance abuse (except tobacco/nicotine).
    • Pregnancy, as determined by the participant's self-report prior to the magnetic resonance imaging (MRI) scan.
  • Healthy Population

    • Primary language other than English or Spanish.
    • Lifetime disorders: any anxiety disorders, OCD, psychotic, bipolar, autism spectrum disorder, intellectual disability; any psychiatric disorder in the past 2 years
    • Current depression disorder.
    • Active psychiatric disorder in the past 2 years.
    • Serious neurological or medical conditions.
    • Current psychoactive medication.
    • Ferromagnetic implants (e.g., pacemaker), metal braces, retainers, tattoos or permanent make-up with metallic content, transdermal medicinal patches that cannot be removed.
    • Active suicidality on the Colombia-Suicide Severity Scale (plan, intent, or behavior).
    • Pregnancy, as determined by the participant's self-report prior to the MRI scan.
  • Parents • Primary language other than English or Spanish.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Image Exposure Arm

    Participants will see various images of facial expressions on a computer screen and provide various rating scores about them.

    Behavioral: Very Brief Exposure to Facial Expressions

Interventions

  • BehavioralVery Brief Exposure to Facial Expressions

    In Very Brief Exposure (VBE): a series of rapid micro- exposures to images depicting feared stimuli (e.g., for SAD, judgmental faces). Each image is followed by a masking stimulus to prevent its conscious recognition. This sequence of image-mask stimuli is repeated many times in an exposure session.

06

What researchers measure

Primary outcomes

  1. Mean Activation of Frontostriatal and Prefrontal Brain Regions to disgusted facial expression in Social Anxiety

    A hypothesis-driven, group-level analysis will test brain activity, measured as Blood Oxygen Level Dependent (BOLD) response, in 4 regions of interest while minimizing Type II error.

    Time frame: Day 2

  2. Mean activation of regions subserving emotion, emotion regulation, and attention processing. Mean deactivation of the Default Mode Network.

    To identify networks of regions subserving information processing functions, we will employ a voxel-wise, linear mixed model with random- and fixed-effects in group-level analyses. The use of a mixed model with random effects will account for highly discrepant variances between and within participants. We will use Statistical Parametric Mapping 12 Software's (SPM12) implementation of Random Field Theory (RFT) at a voxel-wise level to control for false positives. We will assess the cluster-level statistical significance of task-related brain activity using nonparametric, permutation-based statistical techniques.

    Time frame: Day 2

Secondary outcomes

  1. Fear induced by exposure to disgusted facial expression in youth with social anxiety as measured by fear scale

    After each block of 10 disgusted facial expressions, participants rate levels of fear on a 4-point, 1-4 visual analogue scale with these anchor point: "1 - Minimal fear", "2 - Moderate Fear", "3- Much Fear" and "4 - extreme fear".

    Time frame: Day 2

  2. Fear induced by exposure to disgusted facial expression in healthy participants as measured by fear scale

    After each block of 10 disgusted facial expressions, participants rate levels of fear on a 4-point, 1-4 visual analogue scale with these anchor point: "1 - Minimal fear", "2 - Moderate Fear", "3- Much Fear" and "4 - extreme fear".

    Time frame: Day 2

07

Study locations

1 site
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Oct 2026, 26 months.

Of 142 non-industry interventional studies with no phase under Phobia, Social, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 44. This study's 26 months is close to that.

Counting every sponsor, half of 148 studies reached it within 28 months; a quarter within 14 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Jul 29, 2024
StartActual
Aug 14, 2024
Primary completionActual
Oct 26, 2026
CompletionActual
Oct 26, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 28, 2026
Primary completion
Oct 30, 2026→Oct 26, 2026 (actual)
moved 2 times, Oct 19, 2026 – Oct 28, 2026
Study completion
Oct 30, 2026→Oct 26, 2026 (actual)
moved 2 times, Oct 19, 2026 – Oct 28, 2026
Enrollment
80 (estimated)→120 (actual)
Oct 28, 2026
Show all 2 updates
  1. Oct 28, 2026
    Recruiting→Completed
    Primary completion Dec 30, 2026→Oct 26, 2026 (now actual)
    Study completion Jul 30, 2027→Oct 26, 2026 (now actual)
    Enrollment 80 (estimated)→120 (actual)
    + 2 other changes: contact details and site details
  2. Oct 19, 2026
    Primary completion Oct 30, 2026→Dec 30, 2026
    Study completion Oct 30, 2026→Jul 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06526260
Responsible party
Bradley Peterson (Chief, Division of Child & Adolescent Psychiatry, Children's Hospital Los Angeles) — Principal investigator
First posted
Jul 29, 2024
Start date
Aug 14, 2024
Primary completion
Oct 26, 2026
Completion
Oct 26, 2026
Last update
Oct 28, 2026

Study contacts

Bradley S Peterson, MD
principal investigator · Children's Hospital Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion